In the past week, BNGO stock has gone down by -14.65%, with a monthly decline of -13.85% and a quarterly plunge of -41.96%. The volatility ratio for the week is 16.84%, and the volatility levels for the last 30 days are 19.09% for Bionano Genomics Inc The simple moving average for the last 20 days is -16.12% for BNGO stock, with a simple moving average of -64.73% for the last 200 days.
Is It Worth Investing in Bionano Genomics Inc (NASDAQ: BNGO) Right Now?
Moreover, the 36-month beta value for BNGO is 2.21. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for BNGO is 139.11M and currently, short sellers hold a 12.69% of that float. On January 20, 2025, BNGO’s average trading volume was 7.43M shares.
BNGO) stock’s latest price update
Bionano Genomics Inc (NASDAQ: BNGO) has seen a decline in its stock price by -5.89 in relation to its previous close of 0.21. However, the company has experienced a -14.65% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-06 that SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of $0.252 per share of common stock (or per common stock equivalent) and accompanying Warrant. The Warrants have an exercise price of $0.252 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the “Stockholder Approval”).
Analysts’ Opinion of BNGO
Scotiabank gave a rating of “Sector Outperform” to BNGO, setting the target price at $4 in the report published on January 05th of the previous year.
BNGO Trading at -19.74% from the 50-Day Moving Average
After a stumble in the market that brought BNGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.19% of loss for the given period.
Volatility was left at 19.09%, however, over the last 30 days, the volatility rate increased by 16.84%, as shares sank -8.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.61% lower at present.
During the last 5 trading sessions, BNGO fell by -14.65%, which changed the moving average for the period of 200-days by -80.61% in comparison to the 20-day moving average, which settled at $0.2306. In addition, Bionano Genomics Inc saw -32.94% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BNGO
Current profitability levels for the company are sitting at:
- -3.24 for the present operating margin
- -0.02 for the gross margin
The net margin for Bionano Genomics Inc stands at -4.07. The total capital return value is set at -1.99. Equity return is now at value -161.77, with -100.85 for asset returns.
Based on Bionano Genomics Inc (BNGO), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -4.31. The debt to equity ratio resting at 0.46. The interest coverage ratio of the stock is -21.24.
Currently, EBITDA for the company is -213.6 million with net debt to EBITDA at -0.11. When we switch over and look at the enterprise to sales, we see a ratio of 1.22. The receivables turnover for the company is 6.27for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.43.
Conclusion
To wrap up, the performance of Bionano Genomics Inc (BNGO) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
